AI-generated summary
The authors report a randomized controlled study of 60 patients with diabetic peripheral neuropathy, comparing low-level laser therapy at 630 and 819 nm plus conventional care against conventional care alone. They report improved monofilament sensation and differences between groups on part A of the Michigan questionnaire, with no significant difference on part B. The authors conclude that the therapy improved symptoms without side effects.
- Participants
- 60
- Who or what was studied
- Patients with diabetic peripheral neuropathy
- Wavelengths
- 630, 819 nm
- Limits stated in the abstract
- The abstract reports a small sample and the 819 nm wavelength differs from the 810 nm in the title, and part B of the questionnaire showed no significant difference.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sbmu.ac.ir.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm, 819 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Neuropathy, Photobiomodulation, Low-level laser therapy, Laser, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.